Sec61 Portfolio

About Kezar Life Sciences

Kezar Life Sciences is a public biotechnology company developing first-in-class small molecule therapies for chronic diseases, with a primary focus on autoimmune and liver conditions. The company's strategy leverages two distinct technology platforms: selective immunoproteasome inhibition and Sec61 pathway targeting, designed to modulate disease-driving pathways with greater precision than standard immunosuppressants. Its most advanced program, zetomipzomib, is in clinical development for autoimmune hepatitis, following a strategic pivot after discontinuing earlier oncology efforts. Kezar operates as a lean, focused organization navigating the high-risk, high-reward landscape of novel mechanism drug development.

Therapeutic Areas

Other Oncology / Inflammatory Diseases Drugs